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Abstract
The term organoid refers to a miniature version of any organ of the body. An organoid is artificially produced in vitro from stem 
cells or tissue that possess the ability to recapitulate and form the three-dimensional structure of the organ they were once a part 
of . Scientists have learned to create a culture for the organoid that mimics its original micro cellular environment, allowing the 
3-D structure to self-organize and develop into miniature organs . The purpose of this paper is to explore the many advancements 
of organoid technology, and how this progress has benefited the medical field. Organoid technology allows for the observation of 
human organ development and disease, while also providing scientists with the opportunity to test drug interactions with these 
“mini-organs” (Barbuzano, 2017). Organoids also shed light on the future of artificial transplantation, providing replacements 
for dysfunctional organs and tissue. The advancements of organoid technology can potentially revolutionize the field of medicine, 
contributing to the progress of modern biology .
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Introduction
The human body is composed of a variety of tissue-specific 
adult stem cell populations. Adult stem cells of each organ in 
the body possess the ability to self-renew and generate all 
the different cell types present in that specific organ. Recent 
studies allow scientists to apply this knowledge of stem 
cells by culturing them in vitro. Through growing these cells 
under the right conditions, the cells can assemble miniature 
versions of the organs they were once a part of (Drost & 
Clevers, 2017). Through the development of new 3-D tech-
nologies and these ideas, scientists were successful in pro-
ducing artificial organs like the liver, placenta, stomach, lymph 
nodes, and brain. (John D. Loike and Robert Pollack, 2019).
These miniaturized models that mimic real organs have 
been termed ‘organoids’ (Huch, Knoblich, Lutolf, & Martinez-
Arias, 2017). Cells of an organoid can be derived from tissue 
stem cells, embryonic stem cells or induced pluripotent 
stem cells (iPSCs). These cells possess the ability to regener-
ate, allowing the tissue to perform its original function (Prior, 
Inacio , & Huch, 2019).
The ability to create and develop human tissue in a lab 
offers a major breakthrough in modern biology. The ad-
vancement of organoid formation provides scientists with 
the ability to study human development and disease and 
test therapeutic medicine through a personal approach. 
Organoids also offer hope for transplantation of function-
ing organs, eliminating the need for organ donations (Huch, 
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoid research 
can also provide improvement when it comes to animal ex-
perimentation, bioethics, and gene therapy (Xinaris, 2019).
Method
This study was written by researching peer reviewed 
scholarly articles and medical journals to obtain the most 
accurate information on the advancements of organoid 
technology. The data was analyzed and evaluated from 
many different angles, using Touro College’s access to on-
line publications. Additional searches were done through 
Google Scholar, PubMed, and the Science Journal to accu-
mulate relevant information for the study.
Discussion
In 1998, the first successful organoid culture system de-
rived from adult stem cells was the small intestinal organ-
oids of a mouse. This development in organoid research 
led to many discoveries, among them the knowledge 
that Wnt signaling is crucial for maintaining the stem 
cell compartment of the mouse small intestine. Further 
observation brought about the awareness that ectopic 
expression of R-spondin, which communicates with Wnt 
and acts as a Lgr5 ligand, is necessary to include in a cul-
ture of intestinal stem cells as well, for ultimate function 
of the organoid (Drost & Clevers, 2017).
Following these observations and through his own re-
search, Toshiro Sato of Keio University confirmed that the 
artificial inclusion of growth factors present in the organ’s 
original stem cell niche is crucial for optimum efficiency and 
function of the organoid. Sato too researched and studied 
intestine stem cells. He observed that the 3D organoid 
forms from single Lgr5-positive Intestine Stem Cells. He re-
tained the architecture of the authentic intestine, and includ-
ed Wnt/R-spondin, epidermal growth factor (EGF), noggin 
(BMP inhibitor) and an artificial laminin-rich extracellular 
matrix in his in vitro culture. (Drost & Clevers, 2017).
In the body, cells are exposed to intricate and complex 
surroundings where they are involved in many chemical 
interactions (Prior, Inacio, & Huch, 2019). When creating 
an organoid derived from adult stem cells in vitro, the 
stem cell niche of the specific tissue must be duplicat-
ed. Common niche factors necessary when dealing with 
healthy human tissue include, but are not limited to, Wnt, 
R-spondin, noggin and EGF (Drost & Clevers, 2017). 
Inclusion of the precise concentrations of growth factors 
within the culture, and maintaining identical micro-archi-
tecture, allows stem cells to mature into organized tis-
sues, healthy or diseased (Dumont, Heremans, Jan et.al. 
2019). Incorporating these factors in the culture will 
ensure natural interactions among stem cells. It is cru-
cial to mimic these interactions when creating in vitro 
phenotypes to maintain the functions of the cells. This is 




To begin creating an organoid, stem cells must be isolat-
ed from embryonic stages or adult tissues and placed into 
a media with these natural growth factors. Development 
begins from a totipotent cell undergoing rapid cell divi-
sion. The divided cells become more restricted as they 
evolve. At the blastocyst stage, the outer cells mature 
into extraembryonic cells, while the inner cell mass of the 
blastocyst (ICM) is composed of pluripotent cells which 
possess the ability to evolve into tissue of the embryo 
proper. These pluripotent cells are isolated to form the 
embryonic stem cells. The next step in the developmental 
process is gastrulation. During this period, cells of the 
ICM mix together and perform morphogenetic move-
ments that are controlled by signaling factors like Wnt, 
fibroblast growth factor (FGF) and transforming growth 
factor-beta ligands. These signaling factors activate tran-
scription and differentiation into the three germ layers: 
endoderm, mesoderm and ectoderm. After forming the 
three germ layers, the progenitor cells become more 
specific and form the primitive structures of organs, thus 
developing into any tissues and organs of the body (Prior, 
Inacio, & Huch, 2019).
Transplantation and Xenotransplantation
The development of organ transplantation (OT) is “one 
of the most successful advances in modern medicine.” 
For struggling patients with end stage disease, transplan-
tation is usually their last hope to survive. One major 
problem we face today regarding OT is the lack of organ 
availability. We are unable to meet the exceptionally high 
organ demand (Bezinover & Saner, 2019). Arthur Caplan 
of NYU Langone Medical Center reports that the space 
between supply and demand of transplanted organs is 
“worse than it appears to be” (Caplan, 2014).
The phenomenon of creating human 3D cultures that 
duplicate authentic organs allows for extensive use of 
these organoids for many cell therapies, and as a poten-
tial substitute for whole-organ transplantation (Huch, 
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoids have 
been successfully transplanted both orthotopically, in the 
organs, in vivo location, and ectopically, outside of the 
organ’s natural environment. Through both methods of 
transplantation, organoids were successful in undergoing 
cell maturation. These advancements show that organoid 
models can effectively mature and develop when in contact 
with natural signals provided by the in vivo environment, a 
crucial understanding for developing organoid transplan-
tation. An abundance of research in the field of organoid 
transplantation is done to further advance our knowledge 
of its capabilities. The use of immunocompromised mice in 
many experiments has paved the way for great progress. 
When transplanting organoids into these mice for matura-
tion, the organoids were positioned at highly vascularized 
sites, making it easier to control organoid engraftment and 
growth. This allows the organoid to develop for several 
months, without interfering with the mouse’s required 
organ function. Some of these sites include epididymal fat 
pads and underneath kidney capsules (Holloway, Capeling, 
& Spence, 2019).
More recently, scientists were successful in orthoto-
pically transplanting colonic epithelial organoids derived 
from human primary tissue into the murine colon. This 
study was supported by the Research Center Network 
for Realization of Regenerative Medicine project from 
the Japan Agency for Medical Research and Development. 
The experiment was done by removal of epithelial tissue 
from the mice. Results were most efficient when only 
one side of the colon mucosa was removed, to prevent 
obstruction of the murine colon. Following the removal 
of the epithelial cells, human colon organoids were trans-
planted. The xenografted organoids were observed by 
fluorescent endoscopic imaging. After many trials, long-
term engraftment of the human colon organoids was 
eventually successful and was monitored and observed 
by endoscopy for over 6 months. Immunohistochemistry 
of human-specific cytokeratin (KRT8/7) confirmed the 
presence of the human donated epithelium in the colon 
of the mouse. This study broadened our understand-
ing of transplantation through organoids in general, but 
also suggested that the location of the injury must be 
significantly large to successfully create a niche for the 
transplanted organoid. Small injuries requiring engrafted 
tissue, although also allowing for engraftment, proved to 
be more complicated. The tissue did not last as long as 
the engrafted tissue of the case of the larger injury, and 
eventually disappeared over time (Sugimoto, et al., 2017).
Personalized Medicine
Of the many exciting advancements brought about 
through organoid research, the ability to model diseases 
of specific patients in vitro can be of great benefit to med-
icine (Drost & Clevers, 2017). Scientists begin to predict a 
future in which organoid cultures derived from a patient 
can provide correct and effective therapeutic options for 
that particular patient. Induced pluripotent stem cells 
(iPSCs) are skin or blood cells that have been placed back 
into an embryonic-like pluripotent state. This allows the 
cells to mature and develop into any kind of human cell 
and is commonly used for therapeutic purposes. (Huch, 
Knoblich, Lutolf, & Martinez-Arias, 2017).
In regard to oncological patients, these organoids could 
allow testing of drug response, minimizing the load of 
61
What is the Future of Organoids?
therapy. Organoids created from tumor-derived cells are 
obtained from human tumor biopsies. Induced pluripo-
tent stem cells or adult stem cells are taken from the 
biopsy and develop into organoids that mimic the can-
cerous organs. These organoids display identical tumor 
heterogeneity to their in vivo counterparts (Dumont, 
Heremans, Jan et.al. 2019).
Marc van de Wetering, a senior researcher dedicated 
to pediatric oncology, created a biobank of 20 tumor 
organoids derived from patients with colorectal cancer 
(CRC). He characterized the organoids by genes and per-
formed drug testing to observe the correlation of specific 
mutations with drug responsiveness. For example, only 
one of the tumor organoid cultures reacted sensitively 
to LGK974, an inhibitor of Wnt secretion. The sensitivity 
toward this inhibitor was observed to be connected to 
a mutation that was found in the negative Wnt regula-
tor. This study indicated that characteristics of tumors, 
histological and genetic, were mimicked precisely in the 
organoid. These findings can offer a promising future in 
understanding the correlation between tumor genetics 
and drug response (Drost & Clevers, 2017).
Additional studies have also been done to create or-
ganoid models from normal and neoplastic murine and 
human pancreas tissues. Pancreatic cancer is of the most 
fatal malignancies because of its lack of improvement from 
treatment and late diagnosis. Pancreatic organoids can 
develop quickly from cells derived from resected tumors 
and biopsies. These organoids display characteristics that 
are helpful in understanding drug and therapy response of 
the pancreas. Neoplastic organoids that are transplanted 
back into the body, reperform the whole tumor devel-
opment. The organoids develop from early-grade neo-
plasms into “locally invasive and metastatic carcinomas.” 
Organoids are an ideal model for genetic analysis because 
of their ability to be genetically duplicated. Close obser-
vation of murine pancreatic organoids presented altered 
genes and pathways during the onset and progression 
of the disease. After confirming these characteristics in 
human tissue, organoids have been deemed as an effective 
model system for discovering the nature of this deadly 
malignancy (Boj, et al., 2015).
Gene Therapy
Incorporating organoids into gene-editing through the 
use of tools like CRISPR/Cas9 technology offers the pos-
sibility of correcting gene mutations of patients. These re-
paired and healthy genes can then be transplanted into the 
patient (Huch, Knoblich, Lutolf, & Martinez-Arias, 2017). 
CRISPR/Cas9 also allows for manipulation of genes in or-
ganoid cultures, causing drug testing for specific genes to 
be more definitive and reliable (Dumont, Heremans, Jan 
et.al. 2019). Comparing a variety of organoids that are all 
derived from the same iPSC line allows scientists to ob-
serve mutations in specific genes, and the effects on tissue 
specification and development in organs when the genes 
of a patient carry a specific congenital allele. The ability to 
create organoids from the diseased tissue offers various 
methods for clinicians to explore, like computerized drug 
screening tests, or mirroring antibiogram tests to deter-
mine antibiotic susceptibilities (Huch, Knoblich, Lutolf, & 
Martinez-Arias, 2017).
Studies were done to prove the benefits that can be 
gained from adult stem cell-derived organoids with regard 
to hereditary diseases (Drost & Clevers, 2017). Recently, 
advancements in organoids have shown that CRISPR/ 
Cas9 technology can repair cystic fibrosis gene mutations 
(Huch, Knoblich, Lutolf, & Martinez-Arias, 2017). Dr. J.M. 
Beekman of the Regenerative Medicine Center Utrecht, 
along with some colleagues, created a modeled cystic fi-
brosis (CF) in vitro culture. The model was composed of 
cells obtained from CF patients through rectal biopsies, 
creating intestinal organoids. The cystic fibrosis trans-
membrane conductance regulator (CFTR) gene is re-
sponsible for encoding an anion channel that is expressed 
on the surface of epithelial cells. CFTR maintains fluid and 
electrolyte homeostasis. Cystic fibrosis is the result of a 
mutation in the CFTR gene. As a result of this mutation, 
epithelial ion transport is weak, and a build-up of viscous 
fluid becomes present in the respiratory and gastrointes-
tinal tract. CFTR is activated by forskolin, which increases 
intracellular cyclic AMP levels. In a healthy sample of in-
testinal organoids swelling was rapid. However, organoids 
derived from cystic fibrosis patients presented minimal 
swelling in comparison. It is now possible for research-
ers to test various drugs on different CF patient-derived 
organoids, depending on specific CFTR mutations. These 
findings shed light on a future of patient-specific treat-
ment strategies (Drost & Clevers, 2017).
The Liver
There are many diseases associated with the liver, and 
over two million deaths a year worldwide are related 
to liver complications like cirrhosis, viral hepatitis and 
hepatocellular carcinoma (Asrani, Devarbhavi, Eaton, & 
Kamath, 2018). The amount of deaths associated with 
liver disease calls for the advancement of liver organoids 
as treatments for struggling patients. Researchers like 
Meritxell Huch of Gurdon Institute and Takanori Takebe 
from Yokohama City University present their progress in 
the field of liver organoids. They were successful in cre-
ating ductal structures from adult liver and went further 
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to activate these structures to differentiate into hepato-
cytes capable of producing bile acid and maintaining cyto-
chrome activity (Muthuswamy, 2017).
The creation of the liver organoid has been further 
developed through the use of co-culture systems. Many 
studies reported that liver hepatocyte-like cells derived 
from human pluripotent stem cells (hPSCs) in 2D result-
ed in the cells developing immaturely and did not perform 
all functions of mature hepatocytes. Additionally, after 
implantation of these hPSC derived hepatocyte-like cells 
into immunocompromised mice, the cells operated with 
little effectiveness. Due to these poor results, research 
has been dedicated to creating more functional hPSC-de-
rived hepatocytes, to produce a liver organoid model 
that will function more efficiently. The use of co-cultures 
is thought to be the answer to this progress. When ob-
serving mice, researchers found endothelial cells to be a 
crucial cell type in the process of
liver organogenesis. Due to this finding, a hypothesis 
was formed that placing endothelial cells and mesenchy-
mal precursors with the hepatic endoderm in a co-cul-
ture will provide an environment that closely mimics in 
vivo development of the liver. This will give rise to ef-
ficient hepatocyte differentiation, ultimately generating a 
complex human liver bud organoid (Holloway, Capeling, 
& Spence, 2019).
The liver is made up of epithelial, stromal, endothelial 
and mesenchymal cells that all work together to carry 
out its functions. Hepatoblasts are the embryonic progen-
itor cells of the liver. At the time of organogenesis, these 
cells are set aside from the posterior foregut endoderm. 
Hepatoblasts communicate with surrounding signaling 
factors found within the mesenchyme, like FGF, BMP, he-
patocyte growth factor (HGF) and Wnt. These communi-
cations cause the hepatoblasts to evolve and modify until 
they can migrate into the adjacent mesoderm to form 
the liver bud (Prior, Inacio, & Huch, 2019). After creation 
of the hPSC-liver buds, transplantation of the liver buds 
into immunocompromised mice tested the functionality 
of these artificial structures. The hepatocytes of the liver 
bud were proved to be functional due to the presence 
of high sustained levels of albumin within the liver bud 
(Holloway, Capeling, & Spence, 2019). After the liver bud 
is formed, the hepatoblasts expand and differentiate to 
form hepatocytes and biliary epithelium. Meanwhile, the 
mesenchyme generates liver fibroblasts and stellate cells. 
The structure of the liver is formed completely when the 
hepatocytes and cholangiocytes mature further and the 
endothelium and mesenchyme are integrated (Tremblay 
& Zaret , 2005).
Artificial Ovaries
Of all gynecological cancers, epithelial ovarian cancer 
(EOC) is the fifth largest cause of cancer-related deaths in 
European women. EOC patients frequently relapse, with 
an expanding resistance to chemotherapy and targeted 
therapy. Consequently, further research is crucial for the 
advancement of therapy in EOC patients, and organoid 
development seems promising. Models of EOC organoids 
can contribute a constructive platform for drug testing 
and screening, and can ultimately be utilized as a person-
alized in vitro prototype for an individual patient.
High-grade serous ovarian carcinoma (HGSOC) is a 
tumor that arises from the serous tubal intraepithelial 
carcinoma (Dumont, Heremans, Jan et.al. 2019). The fallo-
pian tube epithelium (FTE) has been observed as the site 
where HGSOC originates (Yucer, et al., 2017). Therefore, 
observation of fallopian tube tissue can be very enlighten-
ing in discovering the nature of EOC. Mirjana Kessler of 
the Department of Infectious Diseases and Respiratory 
Medicine, through experimentation, created differentiated 
ovarian organoids from a single fallopian epithelial stem 
cell. These organoid models maintained their stability for 
over several months. This experiment uncovered the ex-
istence of fallopian tube stem cells for the first time. The 
creation of an ovarian organoid requires growth factors 
and microcellular substances, particularly Wnt and Notch 
pathways. The inclusion of Notch is especially important 
because it primarily regulates and maintains the stemness 
of these fallopian epithelial cells (Dumont, et al., 2019).
The urogenital system arises from the intermediate 
mesoderm (IM) of a developing embryo. The Müllerian 
duct within the urogenital system gives rise to the entire 
female reproductive tract (Yucer, et al., 2017). Following 
Kessler’s research, Nur Yucer of the Regenerative Medicine 
Institute at Cedars-Sinai Medical Center was successful 
in constructing Fallopian tube organoids (Dumont et al., 
2019). He created an in vitro culture of the Müllerian duct 
from induced pluripotent stem cells. Yucer then generated 
IM differentiation by adding pro-Mullerian growth factors, 
causing the fallopian tube epithelium to develop. The dif-
ferentiation of the cells was monitored by the addition of 
cell-related markers such as PAX2, GATA3, OSR1, WT1, 
and OVGP1. A 3D growth platform was set up for further 
development and maturation of FTE, which successfully 
caused the tissue to self-organize into an FTE organoid 
structure. When forming the FTE organoid, the canonical 
WNT signaling pathway proved to be crucial. Sub- set of 
WNT gene family members were also included in the 
culture, like WNT3a and WNT4. These genes were nec-
essary for generating the different phases of development 
and maturation of the Müllerian duct. WNT3a and WNT4 
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are also responsible for inhibiting male differentiation 
pathways. After three days of forming the culture, epithe-
lial buds formed from the flat cell sheets. The buds then 
became spheroids, which were put in Matrigel beads with 
pro-mullerian growth factors. The intermediate meso-
derm matured most at day 4, so spheroids were observed 
on days 3 to 6. Inclusion of a weak estrogen, phenol red, in 
Matrigel caused the complete organoid structure to form 
(Yucer, et al., 2017). This finding highlights the necessity 
of estrogen for the differentiating and maturing of the 
Fallopian tube. To maintain and stabilize fully developed 
organoids, both estrogen and progesterone must be pres-
ent. (Dumont, et al., 2019) This is because estrogen alone 
did not maintain the organoids for long periods of time.
More progress has been made in regard to EOC organoid 
research. Dr. Oded Kopper of NewStem efficiently produced 
organoids with epithelial ovarian cancer characteristics. He 
obtained cells from primary tumors or metastatic lesions. 
The organoids he created successfully retained identical ge-
nomic landscapes as the tumors they were derived from. 
Histological aspects and heterogeneity of the tumors were 
also maintained. (Dumont, et al., 2019)
Ovarian cancer organoids can be utilized to observe 
various tumor responses to chemotherapy and for 
drug-screening assays. Xenografting OC organoids also 
allows clinicians to test drug susceptibility in vivo. These 
are some of the many advancements and applications of 
ovarian cancer organoids (Kopper, et al., 2019).
Another major benefit of an artificial ovary is to pre-
serve fertility in patients suffering from cancer. An artificial 
ovary can allow women to fall pregnant after the dam-
aging effects of chemotherapy. (University of Erlangen-
Nuremberg, 2019) Ovarian tissue cryopreservation is the 
process of preserving reproductive potential in oncological 
patients after being exposed to gonadotoxic therapeutic 
agents. (Liverani, et al., 2019) Ovarian tissue cryopreserva-
tion involves the removal of a section or of the complete 
tissue of an ovary. This tissue is then preserved for use 
in the future. (Ben-Aharon, et al., 2016) Cryopreservation 
can be utilized by patients with aggressive malignancies 
who must receive instant gonadotoxic treatment. These 
women do not have the time to receive ovulation induc-
tion, and cryopreservation can be a great benefit. Although 
ovarian tissue cryopreservation can be of great assistance 
for many, cancer patients with moderate-to-high risk of 
ovarian metastasis are at too high of a risk. The process 
of cryopreservation introduces the possibility of malignant 
cells being reimplanted back into the patient.
A promising approach for these high-risk patients is 
the use of artificial ovaries. Isolating follicles from a pa-
tient’s ovarian tissue and reimplanting the follicles into 
an artificial ovary can guarantee that no malignant cells 
will be reintroduced to the patient. (Liverani, et al., 2019) 
Because follicles are isolated in a basement membrane, 
there is no interaction between capillaries, follicular cells, 
white blood cells and nerves. Therefore, there is no threat 
that malignant cells will be introduced back to patients. 
Artificial ovaries make it possible to transplant primor-
dial and primary follicles that were isolated to survive 
and could mature into follicles after transplantation. This 
permits sex hormones to be secreted, regulating oocyte 
maturation to the point where they are capable of fertil-
ization. In the artificial ovary, it is essential for the follicles 
to be supplied with an environment that mimics the nat-
ural human ovary. In order for the follicles to survive and 
develop, interaction with the ovarian extracellular matrix 
(ECM), as well as surrounding ovarian cells must be pres-
ent. For example, ovarian stromal cells are required to 
activate primordial follicles, while endothelial cells are 
necessary for vascularization, providing transportation 
of oxygen and nutrients, paracrine factors, and removal 
of metabolic waste. The presence of the ovarian ECM is 
responsible for maintaining 3D follicle structure, as well 
as other important roles. Therefore, all these factors must 
be present. (Dolmans & Amorim, 2019)
Drs. Teresa Woodruff and Ramille Shah of Northwestern 
University led a team of scientists in creating artifi-
cial ovary structures. The process utilized a 3D printer 
to create the structure that would hold the follicles. A 
stainless steel nozzle was used for the printer, which was 
around the width of a strand of hair. Five layers of gelatin 
filaments were printed at various angles. Tiny cylinders 
were punched through the sheets, creating pores to hold 
mice follicles. Nine mice were involved in the study, and 
all ovaries were removed. Seven of the mice received the 
structures with the follicles, and two received the arti-
ficial structures without follicles. Following the mating 
of these mice with male mice, three mice with artificial 
ovaries produced litters. The artificial ovaries also joined 
with the blood vessels of the mice, allowing for female 
hormones involved in milk production to be made. The 
hormones successfully traveled the mouse bloodstream 
to the breast tissue where it stimulated milk production 
(Piazza, 2018). The ability of an artificial ovary to restore 
endocrine function and provide an environment for follic-
ular development can be extremely useful for oncological 
patients in the future (Cho, Kim, Noh, & Ku, 2019).
Virology
The coronavirus disease-19 (COVID-19), caused by the 
SARS-CoV-2 virus is responsible for over 250,000 deaths 
globally. (Han, et al., 2020) The COVID-19 pandemic 
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proved to the world just how threatening newly surfacing 
viruses can be. Understanding the nature of these viruses 
rests in the use of in vitro cultures capable of viral rep-
lication. The use of organoids is now demonstrating its 
practicality when experimenting the tendencies of these 
deadly viruses.
The novel coronavirus first infected humans in 
December of 2019. Various research groups have been 
experimenting with organoids to better understand the 
nature and tissue tropism of SARS-CoV-2. Josef Penninger 
of the Institute of Molecular Biotechnology, along with 
his colleagues, created capillary and kidney organoids, 
both derived from human iPSCs. Through this research, 
Penninger proved that SARS-CoV-2 can infect both sites 
in the body. These observations help explain the ability of 
the virus to spread throughout the body and the damag-
ing effects on kidney function in infected individuals.
Multiple studies were done to establish whether the 
virus can infect the gastrointestinal tract. Intestinal or-
ganoids derived from adult stem cells were examined and 
presented high levels of angiotensin converting enzyme 2 
(ACE2), a receptor for SARS. The studies displayed that 
enterocytes, the most common intestinal epithelium cell 
type, were infected with the virus. These findings verified 
that the intestine is a potential site for SARS-CoV-2 in-
fection (Clevers, 2020).
Mart Lamers of Erasmus Medical Center, along with his 
colleagues, further investigated the ability of SARS-CoV-2 
to infect the intestines. The human small intestine epithe-
lium is composed of multiple cell types. The experiment 
consisted of 3D structures that displayed all cell types, 
grown in four separate cultures. Each culture displayed 
different amounts of ACE2, proving their ability to be 
infected with SARS-CoV-2. Through the use of electron 
microscopy, Lamers and his colleagues observed that the 
virus caused infection in mature and progenitor entero-
cytes alike. This study suggests that the use of human 
organoid models can provide researchers with beneficial 
resources for examining the nature of SARS-CoV-2 and 
other coronaviruses. (Aaas, 2020)
Since the primary infection site for SARS-CoV-2 is in 
the respiratory organs, research was done to create a 
lung organoid derived from human pluripotent stem cells 
(hPSCs). Development began with the differentiation of 
the hPSCs into definitive endoderm. The cells then fur-
ther progressed into the anterior foregut endoderm 
(AFE) and formed AFE/lung progenitor cells. Further 
specification and maturation of these cells eventually 
formed the lung organoids. The ability of these lung or-
ganoids to provide a platform for modeling COVID-19 
was then put to the test. The cultures were introduced 
to the SARS-CoV-2 virus, and after 24 hours viral RNA 
was detected. The use of immunostaining proved the 
presence of SARS-S protein in the lung organoids. Based 
on this research, scientists can utilize these organoids to 
observe the effects of various drugs on the coronavirus, 
by observing any decrease in the amount of markers 
present from the injected virus. (Han, et al., 2020)
Conclusion
Organoids possess the ability to model tissue structure 
and function with great accuracy, but more research is 
required to take full advantage of organoids. Organoids 
still lack vasculature, immune cells, and other cellular 
components that tissues communicate with and depend 
on in the body (Iakobachvili & Peters, 2017). Without all 
the essential cellular components of an organ, the use 
of organoid in human transplantation will be limited. 
Studying processes where these components are neces-
sary is therefore limited. (Souza, 2018) Efforts to improve 
the vasculature of organoids will provide nutrient supply, 
excretion of toxins and signaling that is present in the 
body. This research is presently making progress, though 
it is demanding and yet to be fully incorporated into stan-
dard tissue culture facilities. (Iakobachvili & Peters, 2017) 
Organoid technology brings up many ethical questions 
as well. For example, what might happen if scientists can 
successfully create a brain organoid? Utilizing a brain or-
ganoid for drug testing would be helpful, but it may pose 
an ethical issue to transplant this organoid into a patient. 
These matters must be addressed in the future. However, 
we do know that organoid technology is adding a whole 
new dimension to the medical field.
References
Aaas. (2020, May 1). Organoid models reveal how 
the COVID-19 virus infects human intestinal cells. 
Retrieved June 5, 2020, from https://www.eurekalert.
org/pub_releases/2020-05/aaft-omr050120.php (Links to 
an external site.)
Asrani , S. K., Devarbhavi , H., Eaton, J., & Kamath , P. S. 
(2018, September 26). Burden of Liver Diseases in the 
World. Retrieved June 2, 2020, from https://pubmed.
ncbi.nlm.nih.gov/30266282 (Links to an external site.)
Barbuzano, J. (2017, November 7). Organoids: A new 
window into disease, development and discovery. 
Retrieved June 2, 2020, from https://hsci.harvard.edu/
organoids (Links to an external site.)
Ben-Aharon, I., Abir, R., Perl, G., Stein, J., Gilad, G., 
Toledano, H., ... Ash, S. (2016, August 9). Optimizing the 
65
What is the Future of Organoids?
process of fertility preservation in pediatric female 
cancer patients – a multidisciplinary program. Retrieved 
June 9, 2020, from https://bmccancer.biomedcentral.com/
articles/10.1186/s12885-016-2584-7
Bezinover , D., & Saner, F. (2019). Organ transplantation 
in the modern era. Retrieved June 2, 2020, from https://
bmcanesthesiol.biomedcentral.com/track/pdf/10.1186/
s12871-019-0704-z (Links to an external site.)
Boj , S. F., Hwang, C., Baker, L. A., Vries, R. G. J., Clevers, 
H., & Tuveson , D. A. (2015, January 15). Organoid 
Models of Human and Mouse Ductal Pancreatic 
Cancer. Retrieved June 2, 2020, from https://www.
cell.com/cell/fulltext/S0092-8674(14)01592-X?_retur-
nURL=https://linkinghub.elsevier.com/retrieve/pii/S00 
9286741401592X?showall=true (Links to an external 
site.)
Caplan, A. (2014, March 1). Bioethics of organ transplan-
tation. Retrieved from https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3935394/ (Links to an external site.)
Cho, E., Kim, Y. Y., Noh, K., & Ku, S. Y. (2019, July 10). A 
new possibility in fertility preservation: The artificial 
ovary. Retrieved June 9, 2020, from https://onlinelibrary.
wiley.com/doi/full/10.1002/term.2870
Clevers, H. (2020, June 1). COVID-19: organoids go viral. 
Retrieved June 4, 2020, from https://www.nature.com/
articles/s41580-020-0258-4
Dolmans, M.-M., & Amorim, C. A. (2019, November 12). 
FERTILITY PRESERVATION: Construction and use of 
artificial ovaries in: Reproduction Volume 158 Issue 5 
(2019). Retrieved June 9, 2020, from https://rep.bioscien-
tifica.com/view/journals/rep/158/5/REP-18-0536.xml
Drost, J., & Clevers, H. (2017, March 15). Translational 
applications of adult stem cell-derived organoids. 
Retrieved June 2, 2020, from https://dev.biologists.org/
content/144/6/968.long (Links to an external site.)
Dumont, S., Jan, Z., Heremans, R., Gorp, T. V., Vergote, I., 
& Timmerman, D. (2019, November 8). Organoids of 
epithelial ovarian cancer as an emerging preclinical in 
vitro tool: a review. Retrieved June 2, 2020, from https://
ovarianresearch.biomedcentral.com/articles/10.1186/
s13048-019-0577-2 (Links to an external site.)
Han, Y., Yang, L., Duan, X., Duan, F., Nilsson-Payant, B. E., 
Yaron, T. M., ... Chen, S. (2020, January 1). Identification of 
Candidate COVID-19 Therapeutics using hPSC-derived 
Lung Organoids. Retrieved June 5, 2020, from https://
www.biorxiv.org/content/10.1101/2020.05.05.079095v1.
full
Holloway, E. M., Capeling, M. M., & Spence, J. R. (2019, 
April 15). Biologically inspired approaches to enhance 
human organoid complexity. Retrieved June 2, 2020, 
from https://dev.biologists.org/content/146/8/dev166173 
(Links to an external site.)
Huch, M., Knoblich, J. A., Lutolf, M. P., & Martinez-Arias, 
A. (2017, March 15). The hope and the hype of organ-
oid research. Retrieved June 2, 2020, from https://dev.
biologists.org/content/develop/144/6/938.full.pdf (Links 
to an external site.)
Iakobachvili, N., & Peters, P. J. (2017, December 5). 
Humans in a Dish: The Potential of Organoids in 
Modeling Immunity and Infectious Diseases. Retrieved 
June 5, 2020, from https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC5723307/
Kopper, O., Witte, C. J. de, Lõhmussaar, K., Valle-Inclan, J. 
E., Hami, N., Kester, L., ... Clevers, H. (2019, April 22). An 
organoid platform for ovarian cancer captures intra- and 
interpatient heterogeneity. Retrieved from https://www.
nature.com/articles/s41591-019-0422-6 (Links to an 
external site.)
Liverani, L., Raffel, N., Fattahi, A., Preis, A., Hoffmann, 
I., Boccaccini, A. R., ... Dittrich, R. (2019, February 4). 
Electrospun patterned porous scaffolds for the support 
of ovarian follicles growth: a feasibility study. Retrieved 
June 9, 2020, from https://www.nature.com/articles/
s41598-018-37640-1
Loike, J. D., & Pollack, R. (2019, August 23). Opinion: 
Develop Organoids, Not Chimeras, for Transplantation. 
Retrieved June 2, 2020, from https://www.the-scientist.
com/news-opinion/opinion--develop-organoids--not-chi-
meras--for-transplantation-66339 (Links to an external 
site.)
Muthuswamy, S. K. (2017, March 15). Bringing Together 
the Organoid Field: From Early Beginnings to the Road 
Ahead. Retrieved June 2, 2020, from https://pubmed.ncbi.
nlm.nih.gov/28292842/ (Links to an external site.)
Piazza, G. (2018, February 22). Making artifi-
cial ovaries. Retrieved June 9, 2020, from https://
www.nih.gov/news-events/nih-research-matters/
making-artificial-ovaries
Prior, N., Inacio , P., & Huch , M. (2019, July 11). Liver or-
ganoids: from basic research to therapeutic applications. 
Retrieved June 2, 2020, from http://europepmc.org/arti-
cle/MED/31300517 (Links to an external site.)
Souza, N. de. (2018, January). Organoids A brief overview 
of stem cell-derived organoids: how they are made 
66
Michelle Freilich
and what the challenges are. Retrieved June 5, 2020, 
from https://www.nature.com/articles/nmeth.4576.
pdf?origin=ppub
 Sugimoto, S., Ohta, Y., Fujii, M., Matano, M., Shimokawa, 
M., Nanki, K., ... Sato, T. (2017, December 28). 
Reconstruction of the Human Colon Epithelium In Vivo. 
Retrieved June 2, 2020, from https://www.sciencedirect.
com/science/article/pii/S1934590917304642 (Links to an 
external site.)
Tremblay , K. D., & Zaret , K. S. (2005, April 1). Distinct 
Populations of Endoderm Cells Converge to Generate 
the Embryonic Liver Bud and Ventral Foregut Tissues. 
Retrieved June 2, 2020, from https://pubmed.ncbi.nlm.
nih.gov/15766750/ (Links to an external site.)
University of Erlangen-Nuremberg. (2019, February 
28). A new method for developing artificial ovaries. 
ScienceDaily. Retrieved June 9, 2020 from www.science-
daily.com/releases/2019/02/190228141319.htm
Xinaris, C. (2019, October). Organoids for replace-
ment therapy: expectations,... : Current Opinion 
in Organ Transplantation. Retrieved June 2, 2020, 
from https://journals.lww.com/co-transplantation/
Abstract/2019/10000/Organoids_for_replacement_ther-
apy__expectations, .9.aspx (Links to an external site.)
Yucer, N., Holzapfel, M., Vogel, T. J., Lenaeus, L., Ornelas, 
L., Laury, A., ... Svendsen, C. N. (2017, September 6). 
Directed Differentiation of Human Induced Pluripotent 
Stem Cells into Fallopian Tube Epithelium. Retrieved June 
2, 2020, from https://www.nature.com/articles/s41598-
017-05519-2 (Links to an external site.)
